Full Press Release Details
Biotechnology Holdings Updates Corporate Treasury Policy to Include Cryptocurrency
Calif., August 13, 2025-LIXTE Biotechnology Holdings, Inc. ("LIXTE" or the "Company") (Nasdaq:
LIXT and LIXTW), a clinical stage pharmaceutical company, today announced that its Board of Directors has approved a strategic capital
allocation initiative to acquire cryptocurrency as part of its corporate treasury. The Board approved allocation of up to 25 percent
of its treasury to cryptocurrencies, including Bitcoin and potentially other digital assets as it deems appropriate.
timing and size of any such transactions will depend on prevailing market conditions and other strategic considerations. LIXTE will continue
to closely monitor developments in the digital asset space and retains the flexibility to adjust its holdings.
Company intends to hold all cryptocurrency assets with a fully regulated and compliant custodian. All future transactions will adhere
strictly to applicable financial, legal and audit regulations to ensure transparency, security and full regulatory compliance.
updated treasury policy is based on our conviction in the long-term potential of cryptocurrency to hedge our existing treasury assets,
as well as delivering meaningful returns for shareholders," said Geordan Pursglove, Chairman and Chief Executive Officer of LIXTE.
"This initiative also reflects the Board's broader vision for LIXTE's growth and commitment to enhancing long-term
LIXTE Biotechnology Holdings, Inc.
Biotechnology Holdings, Inc. is a clinical-stage pharmaceutical company focused on new targets for cancer drug development and developing
and commercializing cancer therapies. LIXTE has demonstrated that its first-in-class lead clinical PP2A inhibitor, LB-100, is well-tolerated
in cancer patients at doses associated with anti-cancer activity. Based on extensive published preclinical data (see www.lixte.com),
LB-100 has the potential to significantly enhance chemotherapies and immunotherapies and improve outcomes for patients with cancer.
lead compound, LB-100, is part of a pioneering effort in an entirely new field of cancer biology - activation lethality -
that is advancing a new treatment paradigm. LIXTE's new approach is covered by a comprehensive patent portfolio. Proof-of-concept
clinical trials are currently in progress for Ovarian Clear Cell Carcinoma, Metastatic Colon Cancer and Advanced Soft Tissue Sarcoma.
Additional information about LIXTE can be found at www.lixte.com.
Statement Disclaimer
announcement contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, and Section
21E of the Securities Exchange Act of 1934. For example, statements regarding the Company's financial position, business strategy
and other plans and objectives for future operations, and assumptions and predictions about future activities, including the continuing
development of proprietary compounds, the planning, funding, coordination and potential results of clinical trials, the patent and legal
costs to protect and maintain the Company's intellectual property worldwide, are all forward-looking statements. These statements
are generally accompanied by words such as "intend," anticipate," "believe," "estimate," "potential(ly),"
"continue," "forecast," "predict," "plan," "may," "will," "could,"
"would," "should," "expect" or the negative of such terms or other comparable terminology.
Company believes that the assumptions and expectations reflected in such forward-looking statements are reasonable, based on information
available to it on the date hereof, but the Company cannot provide assurances that these assumptions and expectations will prove to have
been correct or that the Company will take any action that the Company may presently be planning. However, these forward-looking statements
are inherently subject to known and unknown risks and uncertainties. Actual results or experience may differ materially from those expected
or anticipated in the forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited
to, regulatory policies, available cash resources, research results, competition from other similar businesses, and market and general
are urged to read the risk factors set forth in the Company's filings with the United States Securities and Exchange Commission
at https://www.sec.gov. The Company disclaims any intention or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or otherwise.
more information about LIXTE, contact:
Phone: (631) 830-7092; Investor Phone: (888) 289-5533
Inc. Investor Relations pwinvestor@pondel.com
Pondel: (310) 279-5965; Laurie Berman: (310) 279-5962